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consumption of walnuts is associated with reduced risk of cardiovascular disease, there is inconsistent 
evidence for the impact of walnut consumption on markers of glycaemic control. This systematic review 
and meta-analysis aimed to examine the effect of walnut consumption on markers of blood glucose 
control. A systematic search of Medline, PubMed, CINAHL and Cochrane databases (to 2nd March 2019) 
was conducted. Inclusion criteria were randomised controlled trials conducted with adults which 
assessed the effect of walnut consumption on: fasting blood glucose and insulin, glycated haemoglobin, 
and Homeostatic Model Assessment of Insulin Resistance. Random effects meta-analyses were 
conducted to assess the weighted mean differences (WMD) for each outcome. Risk of bias in studies 
was assessed using the Cochrane Risk of Bias tool 2.0. Sixteen studies providing 18 effect sizes were 
included in the review. Consumption of walnuts did not result in significant changes in fasting blood 
glucose levels (WMD: 0.331 mg/dL [95% confidence intervals: -0.817, 1.479]) or other outcome measures. 
Studies were determined to have either 'some concerns' or be at 'high risk' of bias. There was no evidence 
of an effect of walnut consumption on markers of blood glucose control. These findings suggest that the 
known favourable effects of walnut intake on cardiovascular disease are not mediated via improvements 
in glycaemic control. Given the high risk of bias observed in the current evidence base, there is a need for 
further high quality randomised controlled trials. 
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Type 2 diabetes mellitus (T2DM) is a chronic disease increasing in global prevalence. While 
habitual consumption of walnuts is associated with reduced risk of cardiovascular disease, 
there is inconsistent evidence for the impact of walnut consumption on markers of glycaemic 
control. This systematic review and meta-analysis aimed to examine the effect of walnut 
consumption on markers of blood glucose control. A systematic search of Medline, PubMed, 
CINAHL and Cochrane databases (to 2nd March 2019) was conducted. Inclusion criteria 
were randomised controlled trials conducted with adults which assessed the effect of walnut 
consumption on: fasting blood glucose and insulin, glycated haemoglobin, and Homeostatic 
Model Assessment of Insulin Resistance. Random effects meta-analyses were conducted to 
assess the weighted mean differences (WMD) for each outcome. Risk of bias in studies was 
assessed using the Cochrane Risk of Bias tool 2.0. Sixteen studies providing 18 effect sizes 
were included in the review. Consumption of walnuts did not result in significant changes in 
fasting blood glucose levels (WMD: 0.331 mg/dL [95% confidence intervals: -0.817, 1.479]) 
or other outcome measures. Studies were determined to have either ‘some concerns’ or be at 
‘high risk’ of bias. There was no evidence of an effect of walnut consumption on markers of 
blood glucose control. These findings suggest that the known favourable effects of walnut 
intake on cardiovascular disease are not mediated via improvements in glycaemic control. 
Given the high risk of bias observed in the current evidence base, there is a need for further 
high quality randomised controlled trials. 
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Nutrition plays an increasingly important role in the prevention of chronic diseases including 
coronary heart disease and type 2 diabetes mellitus (T2DM) 
(1,2)
. The global prevalence of 
T2DM is increasing. In 2017, 424.9 million adults globally had diabetes, and this is projected 
to increase to 628.6 million by 2045 
(3)
. Research has demonstrated that lifestyle strategies 
such as dietary changes are effective for the prevention and management of T2DM 
(4)
. While 
dietary patterns exert the effect, they are the sum of individual food choices. There is 
therefore a need to establish the evidence for individual foods which may aid in the 
prevention of T2DM, as well as improve disease management for persons already diagnosed.  
Walnuts are part of the nut category of foods but stand out for their high polyunsaturated fatty 
acid content 
(5)
 which is aligned to cholesterol lowering effects. This, and other components 
in walnuts and nuts generally contribute to reduced risk of coronary heart disease. For the 
food category of nuts, habitual consumption has been associated with the reduced risk of 
coronary heart disease 
(6-10)
 but the evidence base for T2DM is less consistent. Recent 
systematic reviews of observational and clinical studies have reported conflicting results, 
with an inverse relationship between nut intake and risk of T2DM found by one review 
(7)
, 
yet no association reported in others 
(6,8,11)
. Inconsistent results have also been reported when 
the effect of nut consumption on markers of glycaemic control has been investigated. In a 
systematic review restricted to individuals with T2DM, nut consumption was found to 
improve glycated haemoglobin (HbA1c) and fasting glucose levels, with no impact on fasting 
insulin or homeostasis model assessment of insulin resistance (HOMA-IR) (12). Conversely, 
favourable effects of nut intake on fasting insulin and HOMA-IR were found in another 
review, although no effect on HbA1c or fasting glucose was found 
(13)
. To our knowledge, an 
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T2DM or markers of glycaemic control has not been conducted to clarify these inconsistent 
results.  
Given the variation in composition of different types of nuts, there is value in considering the 
impact of individual nut categories. As stated earlier, walnuts, are distinguishable from other 
nuts by virtue of a high polyunsaturated fatty acid content, including alpha-linolenic acid, 
while also delivering dietary fibre and phytochemicals 
(5,14)
. A past analysis of the Nurses’ 
Health Study found increased consumption of walnuts was associated with reduced incidence 
of T2DM, although the relationship may be partly mediated by body mass index 
(15)
. There 
may be a number of reasons for this observation. For example, secondary analysis from 
dietary trials 
(16,17)
 demonstrated that provision of walnuts  appeared to support changes in 
overall diet quality. Here, the consumption of walnuts could be implicated in whole-of-diet 
effects for behavioural as well as biological reasons. With these issues in mind, the aim of 
this systematic review and meta-analysis was to examine the effect of walnut consumption on 
markers of blood glucose control (fasting blood glucose, fasting insulin, HbA1c, and HOMA-
IR) in adults.  
 
Methods 
This systematic review was conducted according to the recommendations of the Cochrane 
Handbook for Systematic Reviews of Interventions (18), and was reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(19)
 (Supplementary Data 1). The protocol for the review was prospectively registered with 
PROSPERO, the International Prospective Register of Systematic Reviews 
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To be eligible for inclusion in this review, studies were required to meet the following 
inclusion criteria: (1) randomised controlled trial study design (including parallel and 
crossover designs, and studies where participants were randomised at either the individual or 
cluster level); (2) studies conducted with humans aged 18 years or older; (3) studies assessing 
the effect of consuming walnuts (as a whole or processed nut, or oil form) on biological 
markers of blood glucose control (fasting blood glucose, HbA1c, fasting insulin, HOMA-IR); 
(4) studies where the effect of walnut consumption could be isolated from other food sources 
or interventions such as physical activity programs. Eligible studies were not limited to those 
published in English, or by study duration.  
Data sources 
A systematic search of the databases MEDLINE (EBSCO), PubMed, Cumulative Index to 
Nursing and Allied Health Literature (EBSCO) and Cochrane Central Register of Controlled 
Trials was conducted by EN. Date restrictions were not applied, and the databases were 
searched on 2 March 2019. Both MEDLINE and PubMed were searched to ensure recent 
studies were detected, in line with recommendations by Rosen and Suhami 
(20)
. Where 
possible Medical Subject Headings in addition to free-text search terms were used in the 
search (20). Reference lists of eligible articles and relevant review articles were also reviewed 
for potential studies. An example of the search strategy is available in Supplementary Data 2. 
Articles were initially processed using Endnote X8 (2017, Endnote X8.1 [software]) 
including removal of duplicates, before being transferred into Microsoft Excel (2016, 
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Articles were screened in duplicate based on the title and abstract. In the case that an abstract 
was not available or did not provide sufficient information to draw a conclusion regarding 
eligibility, the full text articles were retrieved for further review. Following screening, full 
text articles were reviewed in duplicate against the eligibility criteria. In the case that multiple 
articles reported results from a single study, all associated articles were checked to avoid 
duplication of study populations in the analysis. Where multiple articles reported different 
information for the outcomes of the same study, all relevant articles were included and linked 
together, as recommended by the Cochrane Handbook 
(18)
. When multiple articles reported 
the same outcomes from a single study, the article reporting the longest follow up period was 
included in the review.  
Data extraction 
The following data were extracted from each study: citation, country, study design, sample 
size, participant age and body mass index, participant health status, study duration, walnut 
form, dose of walnuts, details of control arm, background diet, and the percentage dietary fat 
consumed in the intervention diet. Aggregate outcome data was extracted from each study. 
Where possible, the mean changes in the relevant biomarker outcomes and the respective 
standard deviation (or standard error/95% confidence interval) were obtained. When these 
data were not available, the mean final values and the respective standard deviation (or 
standard error/95% confidence interval) were retrieved as outlined in the Cochrane Handbook 
for Systematic Reviews of Interventions (18). Where median and interquartile range were 
provided, these were converted to mean and standard deviation using the formula developed 
by Wan et al. (21). As one study (22) provided only pooled standard error for the intervention 
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the published study did not provide adequate information, study authors were contacted for 
additional details. Where available, data from intention-to-treat analyses was extracted for 
use in the meta-analysis. Where this was not available, data from per protocol analyses were 
used, and the impact of these approaches on study results were considered in the risk of bias 
assessment (outlined below).  
Abstract screening, full text review, and data extraction were conducted independently by 
two authors (EN and VG), with any disagreements were resolved via consensus. Where 
consensus could not be reached a third author was consulted (YP). 
Risk of bias assessment 
The Cochrane Collaboration Risk of Bias tool 2.0 
(23)
 was used to determine the risk of bias in 
the included studies, with the effect of assignment to the interventions considered. EN and 
VG independently appraised the risk of bias and disagreements were resolved by discussion 
until consensus was reached.  
Data synthesis 
Stata IC (version 15.1, StataCorp LLC, USA) was used to conduct random effects meta-
analyses, using the metan command (using the randomi option for random effects). This 
command uses the DerSimonian and Laird method with the heterogeneity estimate taken 
from the inverse variance fixed effect model
(24,25)
. Sensitivity analyses were also conducted 
using the random-effects model with Hartung-Knapp-Sidik-Jonkman adjustment
(26)
. 
Weighted mean differences (with 95% confidence intervals) in change or final mean values 
for each outcome were calculated. As both parallel and cross-over studies were included in 
the review, both study designs were initially analysed the same way, using a paired analysis. 
This approach was used as it is the most conservative method for managing cross-over 
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analysis of cross-over studies with correlation coefficients of 0.25, 0.5, and 0.75, in order to 
determine if this analysis underweighted the cross-over studies, as conducted in our previous 
review on nuts as a food group 
(27)
. In the case of two studies which included more than one 
eligible intervention group and corresponding control groups
(17,28)
, study groups were 
included in meta-analyses as separate effect sizes. Sensitivity analyses were then further 
conducted to examine the effect of pooling these separate study groups on results. Meta-
analyses were conducted using available cases analyses, with attrition addressed as part of the 
risk of bias assessment (outlined below).  
The I
2
 test statistic was used to estimate the proportion of total variation attributable to the 
between-study heterogeneity (29). In line with the guidance of Higgins et al.(29), I2 values of 
25%, 50%, and 75% were taken to indicate low, moderate, and high heterogeneity. Contour 
funnel plots were created to determine the presence of small study effects for outcomes with 
10 or more effect sizes
(30)
. An Egger’s test was then conducted to examine the extent of 
funnel plot asymmetry 
(31)
. ‘Leave-one-out’ sensitivity analyses were conducted to explore 
the effect of removing each individual study from the meta-analyses. In addition, to explore 
the effects in whole walnuts only, sensitivity analyses were conducted excluding studies 
using walnut oil
(28,32)
. Pre-specified sub-group analyses (based on study quality, study 
duration (less than three months versus more than three months, aligning with the approaches 
used in previous meta-analyses of nut consumption
(12,33)
), and health status of participants) 
were conducted to explore differences in the magnitude of effects between the sub-groups. In 
addition, post hoc sub-group analyses were conducted based on the dose of walnuts 
consumed (<50 g per day vs >50 g per day, based on dose sub-groups used in a previous 
meta-analysis of nut consumption 
(33)
), and the percentage of total dietary fat provided by the 
intervention diet (<37% vs >37% per day, based on previous research which found beneficial 
effects of fat substitution at total fat intakes <37%
(34)
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where there were at least 10 effect sizes per outcome in total 
(18)
, although the number of 
effect sizes per individual sub-group were not restricted.  The relationship between the nut 
dose (in studies exploring whole nuts only) and the study duration, as continuous 
characteristics, were then explored via random-effects meta-regression using the metareg 
command
(35)
 which uses the Knapp-Hartung variance estimator
(36)
, where sample size 
permitted, as recommended by the Cochrane Handbook 
(18)
.  
Quality of the body of evidence 
The quality of the body of evidence (also known as certainty) was then determined using 
GRADE 
(37)
 (GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. 




A total of 3642 records were identified from the systematic search and the review of 
reference lists and review articles. After the removal of duplicates, 1862 records were 
screened, and 68 full-text articles were reviewed for eligibility. A total of 51 articles were 
excluded after full-text review, with the most common reasons for exclusion being: an 
inability to isolate the effects of walnuts on the outcome of interest (n=15), for example when 
walnuts were provided as part of a suite of dietary changes, the article did not report relevant 
outcomes (n=10), and relevant study outcomes were reported in another article included in 
the review (n=10) (Figure 1, Supplementary Data 3).  This resulted in a total of 17 articles 
describing 16 studies included in this review.  Through these articles, n=18 effect sizes were 
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Characteristics of included studies are outlined in Table 1. Eight studies 
(28,32,38-44)
 had a 
parallel study design, while seven 
(22,45-50)
 had a cross-over study design. In addition, one 
study 
(17)
 included features from both a parallel and cross-over design, where the participants 
were randomised to a parallel group (either energy adjusted or ad libitum diet), and each 
group was intervened with a walnut-included diet period, and a walnut-excluded diet period. 
The duration of the included studies range from four days 
(46)
, to one year  
(39,43,44)
. Studies 
were conducted in Germany 
(45,50)













, and Iran 
(32)
. Studies included participants 
who were healthy (inclusive of overweight participants)  
(22,45,50)
, had metabolic syndrome or 
other risk factors for chronic disease 
(17,38,41-43,46-48)
, had type 2 diabetes mellitus 
(28,32,39,40,49)
, 
or included participants with a mixture of these factors 
(44)
.  
Consumption of walnuts 
Walnuts were consumed as whole nuts in 14 of the included studies 
(17,22,38-50)
, and as an oil in 
two of the studies 
(28,32)
. The dose of whole walnuts consumed by participants ranged from 30 
grams (1.06 oz) 
(39-41,44)
 to 56 grams (1.98 oz) per day 
(48,49)
. In three studies walnuts were 
consumed to provide a prescribed proportion of dietary energy (ranging from 18 – 22% of 
total energy) (38,42,43,47), meaning the dose of walnuts differed between the participants. The 
energy value of the walnuts was accounted for in thirteen studies 
(22,38-50)
, either by modelling 
the energy of the walnuts into the dietary prescription, or by encouraging the participants to 
substitute walnuts for other food in their diet. One study 
(17)
 included two different 
intervention groups, with one group accounting for the added energy from the walnuts, 
whereas another group added the walnuts in addition to their regular diet. The background 
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example the Australian Guide to Healthy Eating), as well as habitual diets (with the addition 
of walnuts for the intervention groups). Control groups typically followed the same 
background diet as the intervention group, with the exception of the added walnuts, although 
some studies included a comparison food in their control group (for example olive oil 
(47)
).  
Risk of bias assessment 
The risk of bias assessments are shown in Figure 2 and Supplementary Data 4 and 5. Studies 
were determined to have either ‘some concerns’ regarding the risk of bias, or be at ‘high risk’ 
of bias, with no studies found to be at ‘low risk’ of bias. 
Effect of nut consumption on study outcomes 
The number of effect sizes and studies, as well as the results of each meta-analysis, are shown 
in Table 2 and Figures 3 - 6. Summary data for each study is available in Supplementary Data 
6. Walnut consumption did not result in significant differences in the fasting blood glucose, 
HbA1c, fasting insulin, or HOMA-IR (Table 2 and Figures 3 - 6). Similar results were found 
when conducting sensitivity analyses using Hartung-Knapp-Sidik Jonkman adjustment
(26)
 
(Supplementary Data 7), and when using correlation coefficients of 0.25, 0.5, and 0.75 for 
cross-over studies (Supplementary Data 8).  
Sensitivity analyses demonstrated that pooling separate intervention groups within the same 
study did not substantially the magnitude of the pooled change effect, nor did removing each 
individual study, or restricting analysis to studies exploring whole walnuts only 
(Supplementary Data 9,  10 and 11, respectively). Sub-group analyses and meta-regression 
were conducted where sample size permitted (fasting blood glucose, HbA1c, fasting insulin). 
Overall, the sub-group analyses indicated that a similar magnitude of effect was found across 
the different sub-groups (Supplementary Data 12). Variation in the magnitude of effect was 
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50g/day) for insulin, however, these results should be interpreted with caution due to the 
small number of studies included in the sub-groups. Similar results were observed for the 
meta-regression, which found no significant relationship between the outcomes of interest 
and the walnut dose, treated as a continuous variable, (fasting blood glucose: p=0.953, 
HbA1c: p=0.576; fasting insulin: p=0.711) or study duration, also treated as a continuous 
variable (fasting blood glucose: p=0.663; HbA1c: p=0.300; fasting insulin: p=0.375).  
 
Small study effects 
Contour funnel plots were generated for outcomes with ten or more effect sizes (fasting blood 
glucose, HbA1c, fasting insulin) (Supplementary Data 13). Visual inspection of funnel plots 
and the results of Egger’s test did not indicate funnel plot asymmetry.  
The quality of the body of evidence 
The quality of the body of evidence was determined using GRADE 
(37)
 (Supplementary Data 
14). The quality of the body of evidence was ‘moderate’ for fasting blood glucose, HbA1c, 
and HOMA-IR, after being downgraded due to risk of bias. The quality of the body of 
evidence for fasting insulin was ‘low’, as a result of being downgraded for both risk of bias 
and inconsistency.  
 
Discussion 
This systematic review and meta-analysis pooled the evidence base from randomised 
controlled trials examining the impact of walnut consumption on markers of blood glucose 
control (fasting glucose, HbA1c, fasting insulin, and HOMA-IR). When compared to control 
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markers of blood glucose control was observed. These results did not appear to be affected by 
sensitivity analyses, suggesting the findings were robust across different scenarios for study 
inclusion and analysis 
(18)
.  
The findings are consistent with research on nuts generally. Although there is a strong body 
of evidence linking habitual consumption of nuts with reduced risk of cardiovascular disease 
(6-8,51)
, and a recent report of reduced risk of cardiovascular disease associated with nut intake 
amongst people with T2DM 
(10)
, evidence is less consistent for the effect of nut consumption 
on incident T2DM and markers of blood glucose control. This may be due to the relative 
effects of foods and diets on progression to these two disease states, as well as the study 
designs aimed at exposing any relationships. Foods deliver bioactive compounds which have 
varying influences on disease mechanisms, and the combination of foods (i.e. diet) 
determines the set of nutrients which deliver a form of polypharmacy, or food synergy 
(52)
. 
Although plant-based diets are by nature high carbohydrate, nuts are largely comprised of fat 
and protein. The component effects of nuts on cardiovascular disease have been described 
(53)
, one of which is dietary fat modification which has resultant impacts on blood cholesterol 
levels, a major risk factor for cardiovascular disease 
(54)
. For walnuts specifically, a previous 
systematic review found improvements in total and low-density lipoprotein cholesterol levels 
with consumption 
(55)
. A further prospective study has highlighted the specific areas of heart 
disease in which nut consumption may be having its impact 
(56)
. On the other hand, although 
fatty acids have been implicated in insulin sensitivity 
(34)
, glycaemic control is more 
immediately influenced by carbohydrate in the diet, so any effect of nuts is likely to be seen 
as part of a preventive dietary pattern, as outlined below. 
Importantly, study designs vary in terms of the extent to which the total dietary pattern is 
controlled, and this may influence the ability to expose the influence of a particular food on 
health outcomes 
(57)










ollongong , on 06 M
ay 2020 at 00:29:14 , subject to the Cam
bridge Core term







form the basis of a systematic review no association between the consumption of nuts and 
risk of T2DM 
(6,8)
 has been found, but when intervention studies are the focus, conflicting 
results emerge 
(7,11)
. From a methodological perspective, these inconsistencies may reflect 
differences in the eligibility criteria between reviews, resulting in differences in the number 
and type of studies included. In view of the above, it is interesting to note that only one 
systematic review 
(7)
 included an analysis from the PREDIMED trial 
(58)
 (which showed a 
favourable effect of a Mediterranean diet inclusive of nuts or olive oil on incidence of T2DM 
(59)
). Importantly the background diets in the PREDIMED study were controlled and this may 
have enabled relationships to be better exposed 
(57)
. Nevertheless, conflicting findings are also 
reported by systematic reviews of trials examining the impact of nut consumption on markers 
of blood glucose control, both in individuals with T2DM 
(12)
, and the broader adult population 
(13)
. Our findings are consistent with the latter review 
(13)
 where it was limited to analyses 
specifically examining the impact of walnuts. We build on these findings by including the 
most recent studies, considering the broader at risk population, addressing all available 
durations of study 
(22)
, and using the most up-to-date risk of bias tool
(60)
.  
The relative impact of walnuts within a preventive dietary pattern is another way to consider 
the food-disease relationship. As walnuts are differentiated from other nuts by their high 
polyunsaturated fatty acid content, a desirable impact on cholesterol levels in a low fat diet 
would be expected. However, like other nuts they also deliver dietary fibre, phytochemicals, 
and a number of vitamins and minerals including folate, niacin, magnesium, and potassium 
(61)
. Consumption of tree nuts including walnuts has been found to be associated with 
favourable overall nutrient intakes 
(62,63)
, and in one study, the provision of walnuts 
specifically increased the overall quality of the diets chosen by participants 
(16,17)
. Thus, for 
cuisine reasons, the inclusion of walnuts may help drive better meal and snack choices 
producing a diet more aligned with preventive health outcomes. This behavioural concept 
could also be considered in trials of diets related to the prevention of T2DM, where 
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From a methodological perspective, the assessment of the risk of bias within individual 
studies is essential when considering the overall quality of the body of evidence on a topic 
(64)
. We evaluated risk of bias using the Cochrane Collaboration Risk of Bias tool 2.0, which 
was updated in July 2019 
(23)
. This updated tool was released to overcome challenges 
associated with the previous tool 
(18)
, including inconsistent use amongst researchers, 
difficulties in determining risk of bias in some domains, and difficulties in assessing overall 
risk of bias (60). Applying the 2.0 tool in our review, we found all studies had either ‘some 
concerns’ regarding the risk of bias, or were at ‘high risk’ of bias. Potential bias particularly 
emerged in relation to the randomisation process, often due to a lack of information on 
allocation concealment. It also emerged with the lack of pre-registered protocols detailing 
sufficient information to determine if the results were selectively reported. The literature 
confirms a general trend for insufficient reporting of allocation concealment in randomised 
controlled trials 
(65)
, and problems in identifying selective reporting of outcomes due to the 
lack of pre-registered study protocols 
(66)
. This may reflect the time in which the studies were 
conducted relative to demands by the scientific literature for these standards, but this resulted 
in downgrading the quality of the body of evidence (evaluated using GRADE 
(37)
), for all 
outcomes. These findings suggest a need for more randomised controlled trials with pre-
registered study protocols and better reporting of all aspects of study methodology in 
accordance with current standards.   
There were several strengths to this review. It was conducted and reported according to 
current guidelines
(18,19)
, and included an evaluation of results using a number of sensitivity 
analyses, and examination of the risk of bias using an updated assessment tool. The review 
was also not limited by study duration, in comparison to previous reviews on this topic 
(12,13)
. 
There were also potential limitations, such as the small number of studies available for 
inclusion, limiting the generalizability of results and interpretations of the results of the sub-
group analyses and meta-regression (known to be influenced by the number of available 
observations 
(18)
). Heterogeneity was also observed in participant characteristics, particularly 
health status, and in background and control diets. This variation in control diets has been 
highlighted as a common issue in nutrition meta-analyses, where adding or removing one 
food from the diet will lead to variation in overall kilojoule, macro- and micronutrient 
content
(67)
. Furthermore, in order to ensure the effect of walnut consumption could be 
isolated, studies which tested walnut consumption in combination with other nuts (for 
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of the effect of walnut consumption, separated from that of other nuts, this approach resulted 
in the exclusion of several studies such the PREDIMED study 
(58)
 which used a dose of 30g 
mixed nuts, half of which were walnuts, and this may have influenced results. As outlined 
previously, none of the included studies were found to be at low risk of bias, which may have 
resulted in either under or over-estimating the true intervention effects. In addition, 
limitations associated with meta-analysis methodology should be considered. One such 
limitation is Simpson’s paradox, an ecological effect which can occur in meta-analyses of 
randomised controlled trials, particularly when there are imbalances in the size of study 
groups
(68)
. While this appears unlikely in the present review due to the characteristics of the 
studies
(69)
, it is possible in some circumstances. Finally, while the present review followed 
current guidelines for conducting meta-analyses, it should be noted that alternatives to 
random-effects meta-analyses
(70-72)
, and funnel plots and Egger’s test
(73)
 have been proposed. 
Further consideration of these advances as a component of research focused on meta-analysis 
methodologies is recommended.   
This systematic review and meta-analysis did not find evidence of an effect of walnut 
consumption on markers of blood glucose control, namely fasting glucose, HbA1c, fasting 
insulin, and HOMA-IR. These findings suggest that favourable effects of walnut intake on 
health outcomes such as cardiovascular disease observed elsewhere may not be mediated via 
improvements in glucose control. Given the high risk of bias observed in the current evidence 
base, there is a need for further research on this topic, with a particular emphasis on meeting 
current standards for registering and reporting on randomised controlled trials to reduce the 
risk of bias.  
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*Study included other intervention group which was not relevant to this review, therefore this group was not included in this analysis 
†Treated as comparison group for this analysis 
•Unit reported in study, converted to consistent unit for analysis 
§§Gram weight for dose sub-analysis based on mid-point of range of doses used 
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Abbreviations: BMI: body mass index; CI: confidence intervals; F: female; HC: hypercholesterolemia; M: male; MetS: metabolic syndrome; O: walnut oil; OAD: oral antidiabetic 
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Table 2: Changes in outcomes following walnut consumption, compared to control.  
 












Fasting blood glucose (mg/dL) 15 17 1620 0.331 (-0.817, 1.479), p=0.572 17.4% 
HbA1c (%) 10 12 1290 0.031 (-0.001, 0.063), p=0.057 16.4% 
Fasting insulin (μIU/mL) 9 10 725 0.032 (-1.826, 1.889), p=0.973 53% 
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Figure 1: PRISMA flow diagram of study selection 
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Figure 2: Risk of bias assessment as a proportion of total studies 
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Figure 3: Difference in fasting blood glucose (mg/dL) between walnut consumption and 
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Figure 4: Difference in HbA1c (%) between walnut consumption and control. Diamond 
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Figure 5: Difference in fasting insulin (μIU/mL) between walnut consumption and control. 
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Figure 6: Difference in HOMA-IR between walnut consumption and control. Diamond 












ollongong , on 06 M
ay 2020 at 00:29:14 , subject to the Cam
bridge Core term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114520001415
